Conbercept (Chengdu Kanghong Biotech Co., Ltd., Sichuan, China) is a novel recombinant fusion protein with a high affinity for all vascular endothelial growth factor (VEGF) isoforms.[6,7] Conbercept, a potent VEGF inhibitor, has been approved to protect against various retinal vasculopathies, including wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, retinal vein occlusion, etc.[8,9] This study reports a case of RAM combined with BRAO that was treated successfully with intravitreal conbercept injection. Here, VEGFA is linked to wet macular degeneration.